Swiss National Bank Buys 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Swiss National Bank lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 321,600 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares during the period. Swiss National Bank’s holdings in Regeneron Pharmaceuticals were worth $338,079,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in REGN. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $33,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 3.3 %

NASDAQ REGN opened at $756.81 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market capitalization of $83.17 billion, a PE ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1 year low of $753.69 and a 1 year high of $1,211.20. The business’s 50-day moving average is $985.21 and its 200 day moving average is $1,033.97.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.